RELIEF THERAPEUTICS Collaboration Partner NRx Pharmaceuticals, Inc. has filed a request Breakthrough Therapy Designation for Aviptadil

0 50

Relief has reported that its U.S. collaboration partner has submitted a Breakthrough Therapy Designation Request for Aviptadil in Patients at Immediate Risk of Death with COVID-19 Despite Remdesivir as Well as other Approved Therapies.

The parent company of RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced today that it has filed for a new Breakthrough Therapy Designation request with the US Food and Drug Administration. Patients with Critical COVID-19 and respiratory failure who are at urgent risk of mortality were the focus of the FDA.

The BTD request is based on an FDA request for clinical data comparing the effectiveness of aviptadil to Remdesivir and other approved medications, according to the news release.

Patients administered aviptadil had a statistically significant (P=.03) 2.8-fold increased likelihood of being alive and free of respiratory failure at day 28 and day 60, as well as a highly significant (P=.006) four-fold increased chance of survival, according to the press release.The following link will take you to the corresponding NRx press release.

Leave A Reply

Your email address will not be published.